Vifor Pharma AG
SIX:VIFN
Intrinsic Value
Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of VIFN.
Fundamental Analysis
Balance Sheet Decomposition
Vifor Pharma AG
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 994.5m |
| Receivables | 442.7m |
| Other Current Assets | 441.4m |
| Non-Current Assets | 3.2B |
| Long-Term Investments | 482.2m |
| PP&E | 187.2m |
| Intangibles | 2.4B |
| Other Non-Current Assets | 165.6m |
| Current Liabilities | 981.3m |
| Accounts Payable | 163.1m |
| Accrued Liabilities | 203.6m |
| Other Current Liabilities | 614.6m |
| Non-Current Liabilities | 628.4m |
| Long-Term Debt | 117m |
| Other Non-Current Liabilities | 511.4m |
Earnings Waterfall
Vifor Pharma AG
|
Revenue
|
1.8B
CHF
|
|
Cost of Revenue
|
-671.8m
CHF
|
|
Gross Profit
|
1.1B
CHF
|
|
Operating Expenses
|
-730.6m
CHF
|
|
Operating Income
|
351.8m
CHF
|
|
Other Expenses
|
-207.4m
CHF
|
|
Net Income
|
144.4m
CHF
|
Free Cash Flow Analysis
Vifor Pharma AG
What is Free Cash Flow?
VIFN Profitability Score
Profitability Due Diligence
Vifor Pharma AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Vifor Pharma AG's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
VIFN Solvency Score
Solvency Due Diligence
Vifor Pharma AG's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Score
Vifor Pharma AG's solvency score is 92/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIFN Price Targets Summary
Vifor Pharma AG
According to Wall Street analysts, the average 1-year price target for VIFN is 167 CHF .
Shareholder Return
VIFN Price
Vifor Pharma AG
| Average Annual Return | 1.65% |
| Standard Deviation of Annual Returns | 37.11% |
| Max Drawdown | -46% |
| Market Capitalization | 10.8B CHF |
| Shares Outstanding | 64 891 300 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. The company is headquartered in Sankt Gallen, St. Gallen and currently employs 2,300 full-time employees. The company went IPO on 2003-02-25. The firm operates through a single pharmaceutical segment. The company develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The firm's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The firm also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The firm has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.
You don't have any saved screeners yet
